Regulus identifies third microRNA target in GSK pact
With this discovery, GSK has paid preclinical milestone to Regulus. The agreement between the companies aims to discover and develop compounds targeting four different microRNAs in inflammation and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.